Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.43 |
| ▸ | CPA1 | P15085 | 3/20 | 0.42 |
| ▸ | CPA3 | P15088 | 2/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | CPB1 | P15086 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2943084 | 1.00 | ALPI (0.49) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL12983651 | 0.83 | TSHR (0.39) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL5328680 | 0.83 | ALPI (0.52) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL27871890 | 0.83 | TSHR (0.39) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL7531784 | 0.81 | ALPI (0.50) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL7531787 | 0.81 | ALPI (0.50) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL288097 | 0.80 | CYP1A2 (0.55) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL475786 | 0.80 | CYP1A2 (0.55) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL6573490 | 0.80 | CTRB1 (0.47) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL7444297 | 0.80 | CTRB1 (0.47) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268888-B2 | Therapy of malignant neoplasias | SAMNICK SAMUEL (DE) | 2012-09-18 | — | — | US | disclosed |
| US-20100003268-A1 | Therapy of Malignant Neoplasias | SAMNICK SAMUEL | 2010-01-07 | — | — | US | disclosed |
| EP-1962822-B1 | THERAPY OF MALIGNANT NEOPLASIAS | SAMNICK SAMUEL (DE) | 2010-01-06 | — | — | EP | disclosed |
| EP-1962822-A1 | THERAPY OF MALIGNANT NEOPLASIAS | Samnick, Samuel (DE) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007079953-A2 | IN VITRO METHOD TO PREDICT THE TUMOR SENSITIVITY TO PHARMACOTHERAPY AND ENDORADIOTHERAPY | SAMNICK SAMUEL (DE) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007060011-A1 | THERAPY OF MALIGNANT NEOPLASIAS | SAMNICK SAMUEL (DE) | 2007-05-31 | — | — | WO | disclosed |
| EP-1001764-A4 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | MERCK & CO INC (US) | 2005-08-24 | — | — | EP | disclosed |
| EP-1001764-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | Merck & Co., Inc. (a New Jersey corp.) (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1998053814-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003268-A1 | Therapy of Malignant Neoplasias | VHL, PAH, FAP | ALPI 1074/4885PKM 798/4885PTGS1 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.